1-20 of 80
diffuse large b-cell lymphoma
Close
Sort by
Journal Articles

Frequent mutated B2M, EZH2 , IRF8 , and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Ruben A.L. de Groen, Ronald van Eijk, Stefan Böhringer, Tom van Wezel, Richard Raghoo, Dina Ruano, Patty M. Jansen, Inge Briaire-de Bruijn, Fleur A. de Groot, Karin Kleiverda, Liane te Boome, Valeska Terpstra, Henriette Levenga, Alina Nicolae, Eduardus F.M. Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C.E. den Hartog, Lara H. Bohmer, Pancras C.W. Hogendoorn, Anke van den Berg, Arjan Diepstra, Marcel Nijland, Pieternella J. Lugtenburg, Marie José Kersten, Steven T. Pals, Hendrik Veelken, Judith V.M.G. Bovée, Arjen H.G. Cleven, Joost S.P. Vermaat
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3760–3775.
https://doi.org/10.1182/bloodadvances.2021005215
Published: 2021
Includes: Supplemental data
Journal Articles

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome

Clinical Trials & Observations
Alex F. Herrera, Kwang Woo Ahn, Carlos Litovich, Yue Chen, Amer Assal, Qaiser Bashir, Ruthee-Lu Bayer, Melanie Coleman, Zachariah DeFilipp, Nosha Farhadfar, Matthew Greenwood, Theresa Hahn, Mitchell Horwitz, Caron Jacobson, Samantha Jaglowski, Sylvie Lachance, Amelia Langston, Bassam Mattar, Richard T. Maziarz, Joseph McGuirk, Mohammad A. H. Mian, Sunita Nathan, Adrienne Phillips, Kevin Rakszawski, Henrik Sengeloev, Shalini Shenoy, Robert Stuart, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3528–3539.
https://doi.org/10.1182/bloodadvances.2021004865
Published: 2021
Includes: Supplemental data
Journal Articles

Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

Clinical Trials & Observations
Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, Claire Mauduit, Pierre Sesques, Violaine Safar, Emmanuelle Ferrant, Camille Golfier, Dana Ghergus, Lionel Karlin, Anne Lazareth, Fadhela Bouafia, Gian Matteo Pica, Frédérique Orsini-Piocelle, Clément Rocher, François-Xavier Gros, Marie Parrens, Arthur Dony, Cédric Rossi, Hervé Ghesquières, Emmanuel Bachy, Alexandra Traverse-Glehen, Clémentine Sarkozy
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3227–3239.
https://doi.org/10.1182/bloodadvances.2021004515
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Clinical Trials & Observations
Mirian Brink, Xaver U. Kahle, Joost S. P. Vermaat, Josee M. Zijlstra, Martine Chamuleau, Marie José Kersten, Müjde Durmaz, Wouter J. Plattel, Pieternella J. Lugtenburg, Wendy Stevens, Rogier Mous, Elisabeth G. E. de Vries, Marjolein W. M. van der Poel, Prashant V. Nannan Panday, Gerwin Huls, Tom van Meerten, Marcel Nijland
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2958–2964.
https://doi.org/10.1182/bloodadvances.2021004295
Published: 2021
Includes: Supplemental data
Journal Articles

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

Clinical Trials & Observations
Sophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, Samuel Griolet, Maria Gomes da Silva, Pierre Feugier, Franck Morschhauser, Judith Trotman, Loic Renaud, Richard Greil, Alejandro Martín García-Sancho, Sebastian Grosicki, Koen van Eygen, Christiane Copie-Bergman, Corinne Haioun, Catherine Thieblemont
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2965–2968.
https://doi.org/10.1182/bloodadvances.2021004766
Published: 2021
Includes: Supplemental data
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data
Journal Articles

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, Valdemar Priebe, Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, Elisa Civanelli, Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni
Journal: Blood Advances
Blood Adv (2021) 5 (10): 2467–2480.
https://doi.org/10.1182/bloodadvances.2020003566
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Clinical Trials & Observations
Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2426–2437.
https://doi.org/10.1182/bloodadvances.2021004665
Published: 2021
Includes: Supplemental data
Journal Articles

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

Clinical Trials & Observations
J. J. Eertink, C. N. Burggraaff, M. W. Heymans, U. Dührsen, A. Hüttmann, C. Schmitz, S. Müller, P. J. Lugtenburg, S. F. Barrington, N. G. Mikhaeel, R. Carr, S. Czibor, T. Györke, L. Ceriani, E. Zucca, M. Hutchings, L. Kostakoglu, A. Loft, S. Fanti, S. E. Wiegers, S. Pieplenbosch, R. Boellaard, O. S. Hoekstra, J. M. Zijlstra, H. C. W. de Vet
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2375–2384.
https://doi.org/10.1182/bloodadvances.2021004467
Published: 2021
Includes: Supplemental data
Journal Articles

Treating lymphoma is now a bit EZ-er

Clinical Trials & Observations
Ryan D. Morin, Sarah E. Arthur, Sarit Assouline
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2256–2263.
https://doi.org/10.1182/bloodadvances.2020002773
Published: 2021
Journal Articles

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Clinical Trials & Observations
Toby A. Eyre, William Wilson, Amy A. Kirkwood, Julia Wolf, Catherine Hildyard, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Jaimal Kothari, Christopher P. Fox, Nicolas Martinez-Calle, Andrew McMillan, Mark Bishton, Graham P. Collins, Chris S. R. Hatton
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2229–2236.
https://doi.org/10.1182/bloodadvances.2021004286
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Clinical Trials & Observations
Hyehyun Jeong, Hyungwoo Cho, Hyeyeong Kim, Heejung Chae, Jung-Bok Lee, Kyoungmin Lee, Shin Kim, Sang-wook Lee, Jin-Sook Ryu, Kyung Won Kim, Eun Jin Chae, Jooryung Huh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2142–2152.
https://doi.org/10.1182/bloodadvances.2020003947
Published: 2021
Includes: Supplemental data
Journal Articles

Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen

Zhongying Mo, Scott Wood, Shawn Namiranian, Reina Mizukoshi, Stephanie Weng, In Sock Jang, Celia Fontanillo, Joshua M. Baughman, Arianna Silva-Torres, Michelle Slade, Marwa Khater, Kai Wang, Mark Rolfe, Gang Lu
Journal: Blood Advances
Blood Adv (2021) 5 (7): 2027–2039.
https://doi.org/10.1182/bloodadvances.2020003431
Published: 2021
Includes: Supplemental data
Journal Articles

Functional characterization of PD1 + TIM3 + tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade

Mikaël Roussel, Kieu-Suong Le, Clémence Granier, Francisco Llamas Gutierrez, Etienne Foucher, Simon Le Gallou, Céline Pangault, Luc Xerri, Vincent Launay, Thierry Lamy, Eric Tartour, Daniel Olive, Thierry Fest
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1816–1829.
https://doi.org/10.1182/bloodadvances.2020003080
Published: 2021
Includes: Supplemental data
Journal Articles

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Clinical Trials & Observations
Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1483–1489.
https://doi.org/10.1182/bloodadvances.2020002982
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma

Ayumi Fujimoto, Tatsuhiko Anzai, Takahiro Fukuda, Naoyuki Uchida, Takanori Ohta, Takehiko Mori, Masashi Sawa, Satoshi Yoshioka, Toshihiro Miyamoto, Hitoji Uchiyama, Yuta Katayama, Ken-ichi Matsuoka, Souichi Shiratori, Hideyuki Nakazawa, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Naoto Fujita, Eisei Kondo, Ritsuro Suzuki
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1412–1424.
https://doi.org/10.1182/bloodadvances.2020003735
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Clinical Trials & Observations
Arushi Khurana, Mattia Novo, Grzegorz S. Nowakowski, Kay M. Ristow, Robert J. Spinner, Christopher H. Hunt, Rebecca L. King, Daniel H. Lachance, Thomas M. Habermann, Ivana N. Micallef, Patrick B. Johnston
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1379–1387.
https://doi.org/10.1182/bloodadvances.2020003666
Published: 2021
Includes: Supplemental data
Journal Articles

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Clinical Trials & Observations
Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Sahin, Gila Sellam, Mikkel Z. Oestergaard, Umberto Vitolo, Marek Trněný
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1283–1290.
https://doi.org/10.1182/bloodadvances.2020002690
Published: 2021
Includes: Supplemental data
Journal Articles

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Catherine S. Diefenbach, Brandilyn A. Peters, Huilin Li, Bruce Raphael, Tibor Moskovits, Kenneth Hymes, Jonas Schluter, J. Chen, N. Nora Bennani, Thomas E. Witzig, Jiyoung Ahn
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1194–1198.
https://doi.org/10.1182/bloodadvances.2020003129
Published: 2021
Includes: Supplemental data